Related Experiment Video
Updated: Jun 22, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
HDAC inhibitor-based therapies and haematological malignancy
1Laboratory of Cancer Biology, Department of Clinical Pharmacology, University of Oxford, Oxford, UK.
Summary
Histone deacetylase (HDAC) inhibitors show promise as anticancer agents, particularly for hematological malignancies. Further understanding of their molecular effects is crucial for optimizing clinical applications.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Histone deacetylase (HDAC) activity regulates physiological processes, but aberrant control is implicated in cancer.
- HDAC inhibitors induce tumor cell apoptosis, leading to their development as anticancer agents.
- Clinical trials are ongoing, with notable efficacy in hematological malignancies.
Purpose of the Study:
- To review the molecular mechanisms underlying the anticancer effects of HDAC inhibitors.
- To correlate these molecular insights with the clinical outcomes in hematological malignancies.
Main Methods:
- Literature review of studies on HDAC inhibitors and their anticancer effects.
- Analysis of clinical trial data for HDAC inhibitors in hematological malignancies.
Main Results:
- HDAC inhibition triggers apoptosis in tumor cells.
- Vorinostat is approved for cutaneous T-cell lymphoma.
- Hematological malignancies show a favorable response to HDAC inhibitors.
Conclusions:
- Understanding the molecular basis of HDAC inhibition is key to its clinical application.
- HDAC inhibitors represent a promising therapeutic strategy for hematological cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.